Inhibrx Biosciences Updates on Clinical Trials Progress

Inhibrx Biosciences Inc ( (INBX) ) just unveiled an update.

Inhibrx Biosciences announced updates on its clinical trials for INBRX-106 and ozekibart. The INBRX-106 Phase 2/3 trial, in combination with Keytruda, is progressing with 46 out of 60 patients enrolled for treating head and neck squamous cell carcinoma, with data expected to mature by the second half of 2026. The ozekibart trials have completed enrollment for colorectal cancer and are progressing for Ewing sarcoma, with potential discussions for accelerated FDA approval in 2026.

The most recent analyst rating on (INBX) stock is a Hold with a $100.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.

Spark’s Take on INBX Stock

According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.

Inhibrx Biosciences Inc’s overall stock score is driven by strong technical momentum and positive corporate events, particularly the promising ChonDRAgon study results. However, significant financial challenges and a weak valuation due to negative profitability weigh heavily on the score. The company’s ability to capitalize on its recent clinical successes will be crucial for future performance.

To see Spark’s full report on INBX stock, click here.

More about Inhibrx Biosciences Inc

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates for oncology. The company utilizes advanced protein engineering platforms to create precision-engineered therapeutics, including INBRX-106 and ozekibart, targeting complex disease biology.

Average Trading Volume: 381,097

Technical Sentiment Signal: Buy

Current Market Cap: $1.16B

For a thorough assessment of INBX stock, go to TipRanks’ Stock Analysis page.